Adriana Brune, MD
Dermatology · Corvallis, ORNPI 1699743062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 669 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 30.5% of the total. Among dermatology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 669 payments — averaging $16.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Lilly USA, LLC$895
- Pfizer$846
- Sanofi$616
- Novartis$433
- plus $3K from 19 others
What the payments were for
- Food & beverage$10,50994%
- Education$6306%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 233 | $3,397 |
| Johnson & Johnson | 110 | $1,770 |
| Lilly USA, LLC | 60 | $895 |
| Pfizer | 59 | $846 |
| Sanofi | 32 | $616 |
| Novartis | 21 | $433 |
| UCB, Inc. | 14 | $415 |
| Regeneron Healthcare Solutions, Inc. | 21 | $391 |
| Sun Pharmaceutical Industries Inc. | 16 | $387 |
| Amgen | 19 | $357 |
| Incyte Corporation | 16 | $340 |
| LEO Pharma Inc. | 12 | $244 |
| E.r. Squibb & Sons, L.L.C. | 9 | $187 |
| Dermavant Sciences, Inc. | 8 | $172 |
| Galderma Laboratories, L.p. | 7 | $127 |
| Biofrontera Inc. | 9 | $114 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 7 | $106 |
| Arcutis Biotherapeutics, Inc. | 5 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Dermira, Inc. | 4 | $62 |
| Merz North America, Inc. | 2 | $52 |
| Mayne Pharma Commercial LLC | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $17 |
| Organon | 1 | $11 |
How this compares
$11,138 in reported general payments places this provider in the 90th percentile of 175 dermatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 30 | $622,496 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 40 | $312,279 |
| Humira(Cf) PenAdalimumab | 17 | $163,556 |
| Dupixent PenDupilumab | 33 | $120,882 |
| Taltz SyringeIxekizumab | 11 | $102,611 |
| Humira(Cf)Adalimumab | 15 | $101,964 |
| Tacrolimus | 101 | $9,985 |
| Clobetasol Propionate | 181 | $6,114 |
| Fluorouracil | 63 | $3,586 |
| Doxycycline Hyclate | 26 | $2,949 |
| Calcipotriene | 36 | $2,477 |
| Ketoconazole | 104 | $2,066 |
| Azelaic Acid | 11 | $1,403 |
| Minoxidil | 177 | $1,159 |
| Metronidazole | 27 | $1,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $3,397 | $101,96415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 dermatology providers in Oregon.
Other dermatology in Corvallis
- Sterling FarrerCorvallis$10K
- Jacob BoydCorvallis$7K
- Andrew BlauveltPortland$1.8M
- Benjamin EhstPortland$1.5M
- Jason HawkesPortland$1.5M
- Eric SimpsonPortland$1.4M
- Collin BlattnerThe Dalles$409K
- Alex Ortega LoayzaPortland$122K
- Omar QutubPortland$107K
- Paul HaunPortland$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.